Ensuring Clarity and Understandability of the FDA's Breast Density Notifications

JAMA. 2023 Jan 10;329(2):121-122. doi: 10.1001/jama.2022.22753.
No abstract available

Plain language summary

This Viewpoint discusses the use of breast density notifications to inform women with dense breast tissue of the potential need for supplemental cancer screening, as well as the need to ensure that such notifications are clear and understandable to women of all language backgrounds, literacy levels, educational levels, and socioeconomic backgrounds.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Density*
  • Breast Neoplasms* / diagnostic imaging
  • Breast* / diagnostic imaging
  • Early Detection of Cancer
  • Mammography* / standards
  • United States
  • United States Food and Drug Administration* / legislation & jurisprudence
  • United States Food and Drug Administration* / standards